Biontech Se (BNTX) - News Archive

Sustained Growth and Promising Advances: BioNTech SE s Strategic Momentum in 2024 By BioNTech SE (Nasdaq: BNTX), a pioneering biotechnology company recognized for its trailblazing mRNA technology, has demonstrated a com...

BioNTech SE, a renowned biopharmaceutical company, recently announced its first-quarter financial results and corporate update, highlighting significant developments in the field of personalized immunotherapy. The compa...

BioNTech, a leading biotechnology company based in Mainz, Germany, has announced that it will report its financial results for the first quarter of 2024 on May 6th. In addition to the financial report, the company will...

BioNTech SE, a leading biotechnology company, announced significant findings from a three-year follow-up study of their mRNA-based individualized immunotherapy candidate, autogene cevumeran (BNT122, RO7198457). The tria...

In recent news, BioNTech SE (NASDAQ: BNTX), a prominent biotechnology company, finds itself embroiled in a securities class action lawsuit. The case, which spans from March 30, 2022, to October 13, 2023, has reached a c...

In a recent announcement, Rosen Law Firm, a prominent global investor rights law firm, has advised investors who purchased securities of BioNTech SE (NASDAQ: BNTX) within the Class Period of March 30, 2022, to October 1...